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Objective. Vulvar cancer is a rare disease mainly in older women. HPV and non-HPV induced vulvar cancer reﬂect two types
of oncogenesis. Controversies exist on most recent developments in vulvar cancer incidence, patients, and disease characteristics.
Changesinincidence,ageofdiseaseonset,andtumorsiteinwomentreatedforprimaryvulvarcancerinasingleGermanuniversity
hospital unit will be described. Methods. A retrospective analysis of patient records of women treated between 1994 and 2008 was
performed. The ﬁfteen-year-spanning period was divided into three ﬁve year-spanning cohorts. Descriptive and statistical analyses
were performed. Results. 104 patients were identiﬁed: cohort-1 from 1994 to 1998 (11 patients); cohort-2 from 1999 to 2003 (21
patients); cohort-3 from 2004 to 2008 (72 patients). Mean age (years) was 73.18 (conﬁdence interval (CI): 64.04; 82.33), 58.9 (CI:
52.24; 65.57), and 61.19 (CI: 57.27; 65.12), respectively. Vulvar cancer conﬁned to the region between clitoris and urethra was seen
m o r eo f t e ni nc o h o r t - 3( n = 20) compared to cohort-1 (n = 0) or cohort-2 (n = 1). Conclusion. This analysis supports the notion
of rising incidence of vulvar cancer and a changing pattern of anatomical local extension. Disease onset is not restricted to older
women.
1.Introduction
The incidence of vulvar cancer in women is increasing,
especiallyinyoungerwomen[1–4].Theincidenceofinvasive
vulvar cancer is approximately 2.5 per 100000 women per
year in Germany [2]. For the UK similar age-adjusted inci-
dencerateshavebeenreported[5].Inyoungerwomen,HPV-
infection (mainly type 16) is an important etiological factor
for the induction of squamous cell vulvar cancer [6]. Vulvar
cancer of the elderly is rarely associated with HPV infection
[7], but more often with a history of lichen sclerosus
and preneoplastic lesions [4]. The increase of preneoplastic
lesions has been reported for some countries [4]. Attention
to a woman’s report of vulvar symptoms and careful clinical
examination of the appropriate anatomical region eventually
leading to diagnostic biopsy may contribute to an early
detection of preneoplastic lesions or vulvar cancer [8].
Nevertheless,gynecologistsarefamiliarwithadvancedvulvar
cancer requiring complex surgical interventions [9]. The
o v e r a l ls u r v i v a la f t e r5y e a r sr a n g e sf r o m8 7 %i ns t a g eIt o
22% in stage IV [10, 11]. The phenomenon of contralat-
erally settled metastases originating from one labial site or
widely outspread cancer lesions is well known, whereas the
occurrence of a vulvar cancer lesion conﬁned to the region
between clitoris and urethra is a striking and increasingly
seen phenomenon [3]. These observations on vulvar cancer
incidence and localisation do not apply for all recent reports
[12–15]. The diﬀerences described in the aforementioned
reports are of highest relevance to the current situation.
Thus, further investigations are required to characterise
the developments in vulvar cancer which may lead to
conclusions forvulvar cancerprevention and earlydetection.
Here we report changes in incidence and characteristics
of vulvar cancer in women treated between 1994 and 20082 Journal of Oncology
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Figure 1: Scatterplot of patient’s age at disease onset. The
distribution of 104 patients is shown.
in a single German university hospital unit. The potential
implications for prevention, screening, and early detection
are discussed.
2.MaterialandMethods
A total of 104 women treated for primary vulvar cancer at
the Department of Gynecology, Gynecologic Endocrinology
andOncologyoftheUniversityHospitalMarburg,Germany,
between January 1994 and November 2008 were identiﬁed.
Retrospective analyses were performed; the ﬁfteen-year
period was divided into three ﬁve-year-spanning intervals
to deﬁne three cohorts for further analysis. Among others,
following parameters were derived from conventional or
electronic patient records: age, date of disease onset, his-
tology, tumor stage (FIGO), tumor localisation, previous
nonmalignant vulvar lesions, smoking, menopausal status,
and surgical procedure.
Tumor localisation pattern was analysed with respect to
anatomical site and number of aﬀected sites. Descriptive
analyses of the diﬀerent parameters with ordinal or nominal
scale were performed, showing absolute or relative frequency
distribution.Whereindicated,meanandstandarddeviations
are shown.
Age was tested for normal distribution; the diﬀerences
between the cohorts were tested by ANOVA and post-hoc
comparisons with Games-Howell for signiﬁcance. Kruskal-
Wallis-H test and Fisher’s exact test were used where
indicated.
Statistical evaluations were performed using SPSS for
Windows (SPSS Inc. Chicago, IL, USA)
3. Results
A total of 104 Caucasian women were identiﬁed who were
treated for primary vulvar cancer at the Department of
Gynecology, Gynecologic Endocrinology and Oncology of
the University Hospital Marburg, Germany, between January
1994 and November 2008. The number of patients treated
since 2005 was maintained on a higher level compared to the
numbers in the late nineties of the formercentury (Figure1).
The regional origin of patients is shown in Figure 2.T h e
regional expansion of patient recruitment did not change
during the observation period. The vast majority of patients
were derived from counties close to the hospital located in
Marburg, Hesse, Germany. The incidence of vulvar cancer
increased by six-fold in the county of Marburg-Biedenkopf,
raising from approximately 0.7 per 100000 women per year
(calculated from cohort-1) to 4.2 per 100000 women per
year (calculated from cohort-3). The mean age decreased
(Table1)whencomparingcohort-3(yearofdiagnosis:2004–
2008) with cohort-1 (year of diagnosis: 1994–1998) the
diﬀerence is signiﬁcant (P = .047; ANOVA) as is between
cohort-1 and -2 (P = .031; ANOVA). Age distribution is
depicted by scatterplot (Figure 1), the median age was 76.0,
63.0, and 62.5 years for cohort-1, -2, and -3, respectively.
Cohort-3 included 2 patients younger than 30 years of
age. The number of patients younger than 50 years of age
increased from n = 1 in cohort-1 to n = 7 in cohort-2 and
n = 20 in cohort-3 (P = .048; Kruskal-Wallis test).
Among other parameters, tumor stage (FIGO) is shown
in Table 1. Tumor depths of inﬁltration were not diﬀerent
(Table 1). Preneoplastic lesions surrounding the invasive
vulvar cancer tissue were detected in 40 (38.5%) of all
patients (Table 1). When comparing all women who aged
50 years and older with women younger than 50 years
irrespective of the cohort aﬃliation, preneoplastic lesions
surrounding vulvar cancer were found more often in women
of <50 years (46.5% (n = 13) versus 35.5% (n = 27))
although this diﬀerence is not signiﬁcant (P = .37; Fisher’s
exact test).
The aﬀected site distribution pattern was evaluated.
The proportion of patients with multiple (two or more
anatomical regions) aﬀected sites was lower in cohort 3
(n = 37 (51.4%)) compared to cohort-1 (n = 10 (88%);
P = .02, Fisher’s exact test) or -2 (n = 14(66.6%); 0.32,
Fisher’s exact test). This proportional decrease of multifocal
lesions is a consequence of the increase of unifocal lesions as
a percentage. The increase of number of patients with vulvar
cancer conﬁned to the region between clitoris and urethra is
evident,thenumberishigherincohort-3(n = 20)compared
to cohort-2 (n = 1) and cohort-1 (n = 0). The diﬀerences
regardingthenumberofpatientswithvulvarcancerconﬁned
to the region between clitoris and urethra between cohort-
3 and cohort-1 (P = .02) or cohort-2 (P = .04) were
signiﬁcant (Fisher’s exact test). When comparing all women
younger than 50 years of age with women equal or older
than 50 years irrespective of the cohort aﬃliation, the vulvar
cancer localisation conﬁned to the region between urethra
and clitoris revealed a higher proportion in the younger
women (n = 9 (32.1%) versus n = 12 (15.8%); P = .06,
Fisher’s exact test).
Absence or presence of high-risk HPV was recorded in
16 patients with positive evidence of HPV infection in ﬁve
vulvar cancer samples. During that backdated observation
period, HPV testing was not routinely done in vulvar cancer.
Sixty two of all patients had a negative history regarding
preneoplasticlesions.Previouslichensclerosuswasknownin
22 patients, carcinoma-in-situ in 4 patients. The proportion
of patients with a positive history of either of these two
lesions is shown in Table 1. When comparing all women
who aged 50 years and older with the women younger thanJournal of Oncology 3
Table 1: Data of 104 patients with vulvar cancer treated between 1994 and 2008. Figures give number of patients unless noted otherwise.
Cohort-1 (1994–1998) Cohort-2 (1999–2003) Cohort-3 (2004–2008)
Number 11 21 72
Mean age [years] 73.18 58.90 61.19 P = .047a
95% CI [years] 64.04; 82.33 52.24; 65.57 57.27; 65.12
Age <50 years 1 7 20 P = .048b
Comorbidities: no 1 3 13
Tobacco abuse: yes 2 10 25 n.s.c
Histology
Squamous cell 10 17 63
n.s.b
Nonsqamous cell 1 4
V e r r u c o u s 111
Adenocarcinoma 2
Other 2 2
FIGO
I2 4 3 0
n.s.b
II 4 4 14
III 1 3 5
IV 37
X4 7 1 6
Grading
G 1 356
n.s.b
G2 8 13 57
G3 6
G4 1
GX 31
Depth [mm] mean +/− SD 5.7 (2.1) 3.7 (4.9) 5.3 (5.4) n.s.a
VIN surrounding invasive cancer [%] 9.1 42.8 41.7 P = .03c∗
P = .05c∗∗
History of lichen sclerosus or carcinoma-in-situ [%] 45.5 33.3 20.8 n.s.c
Unifocal lesion 1 7 35 P = .02c∗
ASA
n.s.b
11 1 1 5
2 1 11 28
33 7 2 7
4 011
x 611
Surgery P = .015c∗
Biopsy only 2 P = .03c∗∗∗
Wide excision or partial vulvectomy 5 11 59
Radical vulvectomy 6 8 13
Adjuvant radiation: yes 1 5 14 n.s.c
Alive (May 2009)
Yes 6 20 72
No 1
Not known 5
CI = conﬁdence interval. ASA = American Society of Anesthesiologists’ Physical Status Classiﬁcation. LNE = inguinal lymphadenectomy. SD = standard
deviation. a ANOVA (post-hoc comparisons with Games-Howell). b Kruskal-Wallis test. c Fisher’s exact test. ∗ Cohort-3 versus cohort-1. ∗∗ Cohort-2 versus
cohort-1. ∗∗∗ Cohort-2 versus cohort-3.4 Journal of Oncology
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Figure 2: A: Residential distribution of vulvar cancer patients treated in Marburg. Map depicts the state of Hesse. B: Residential distribution
of vulvar cancer patients treated in Marburg. Map depicts the middle of the state of Hesse.
50 years irrespective of the cohort aﬃliation, the proportion
of patients in the group of younger women with a positive
history of vulvar lesions was only 3.6% (n = 1) compared
with the women of the older group (35.5% (n = 27)) (P =
.001; Fisher’s exact test).
4. Discussion
This retrospective, single centre analysis contributes more
data to a most recent relevant discussion on changes in
incidenceandcharacteristicsofvulvarcancerinwomen.This
single centre 15-year spanning analysis shows an increase of
theincidenceofvulvarcancer,revealsadecreasedmedianage
of the patients at disease onset, and demonstrates an altered
disease site distribution pattern. Our data strongly support
the report by Hampl et al. [3] with respect to incidence, age
of onset and localisation of vulvar cancer.
In the absence of HPV infection, vulvar cancer can
emerge from lesions like lichen sclerosus or carcinoma-in-
situ [6, 8]. The mutation of tumor suppressor genes like
p53 and CDKN2A was found more often in lichen sclerosus
derived malignancies than in HPV-induced external genital
cancers [16]. In addition to genetic alterations, deterioration
in inﬂammatory response reactions and angiogenesis may
develop from lichen sclerosus lesions [17]. An analysis of
invasive squamous-cell carcinomas of the vulva demon-
strated adjacent lichen sclerosus lesions in 32% of the
samples, and with respect to former nomenclature, 77% of
the vulvar cancer samples had adjacent VIN lesions [18].
The rate of adjacent VIN lesions was 40.4% in the herein
presented collective. Furthermore, 22% of the patients had
a positive history for vulvar lichen sclerosus.
HPV infection is a known predisposing factor leading to
vulvarcancer[6,19].HPV16prevalencewas29.3%invulvar
cancer [20]. Since HPV testing was not routinely performed,
one third of the tested samples of vulvar cancer were found
positive for high-risk HPV DNA in this series.
The incidence of vulvar cancer was 1.7 per 100000
women per year in the USA between 1998 and 2003 [21].
This incidence is slightly lower than reported for Germany
[2]. The incidence was increasing over the investigation
period[15,22].Theproportionofwomenwithvulvarcancer
y o u n g e rt h a n5 0y e a r sw a sn e a r l y2 0 %[ 12]. In the current
cohort, this proportion was 26%. More importantly, the
proportion of younger women increased when comparing
the diagnosis date-related cohorts in the most recent cohort
signiﬁcantly compared to cohort 1. This observation is in
accordance with the data reported by Hampl et al. [3]. This
proportional increase of vulvar cancer in women younger
than 50 years was not found in the US population-based
cancer registries [13–15], although an age-adjusted increase
of vulvar cancer incidence over all age groups was reported
[23]. The presented data support the notion of an increase
in vulvar cancer. The service area of the analyzing hospital
did not alter. The number of inhabitants remained fairly
constant during the observation period [24] in the county
of Marburg-Biedenkopf. The incidence of vulvar cancer
increased by six-fold in the county of Marburg-Biedenkopf,
raising from approximately 0.7 per 100000 women per yearJournal of Oncology 5
to 4.2 per 100000 women per year. Small-area analyses are
suitable to detect risk areas [25, 26]. Small area analysis
should include a longer observation period thus avoiding
misleading results [27]. The observation period of our
retrospective analysis is spanning a 15-year interval. The US
and the German reports agree in a signiﬁcant proportion of
women younger than 50 years of age out of all vulvar cancer
patients.
Vulvar cancer conﬁned to the urethra-clitoris region
was found more often in cohort 3 whereas rarely more
than 10 years ago. Similarly, this observation of changes
in the tumor localization pattern was reported by Hampl
et al. [3]. Vulvar cancer located at the labia majora or
minora or at overlapping and multiple sites is the classical
presentation of this disease [28, 29]. Until now there is
no explanation for this observation [3]. Infection by HPV,
chronic or recurrent mechanical irritation, personal life style
including sexual behavior and hygiene, cosmetic products,
other altered molecular cell survival-regulating pathways
leading to initiation and progression of vulvar cancer are
among the hypotheses [22, 30, 31]. Increase and change
in age distribution of vulvar cancer may require conse-
quences for prevention, screening and detection of early
disease.
Until now, there is no established screening procedure
aiming at vulvar cancer, neither for detection of HPV nor
of preneoplastic lesions [1]. Regular gynecological exam-
ination at least once a year or more often if indicated
should contain anamnesis including vulvar symptoms, vul-
var inspection, clinical investigations including for inguinal
lymph nodes, and in case of suspect lesions performing a
vulvoscopy and biopsy to obtain a histological diagnosis
[1, 8]. Any persisting or suspect lesion should be clariﬁed
by histological investigation, a pap smear is not suﬃcient
[1]. Routine testing for HPV infection in asymptomatic
women is not indicated [1]. The surveillance intervals
shouldbescheduledcloserinimmunocompromisedwomen.
Educating women in gynecological diseases is a pivotal
measure in cancer prevention and detection [8]. The role
of immunotherapies and anti-HPV immunization in the
prevention of vulvar cancer is far from being elucidated
[1, 10].
5. Conclusion
Our data conﬁrm an increasing incidence of vulvar cancer
and some characteristics of vulvar cancer including age of
disease onset and lesion localisation, especially monocentric
lesions conﬁned to the clitoris-urethra region. Currently no
speciﬁc screening procedures or prevention measures can be
recommended. Informative education, careful routine gyne-
cological examination at regular intervals and if indicated
additional investigations like vulvoscopy and biopsy can
contribute to the detection of preneoplastic or early vulvar
cancer lesion. Research has to further elucidate the diﬀerent
pathways leading to vulvar cancer, evaluating the preventive
and therapeutic potential of immunomodulating measures
like topical therapies or HPV vaccination.
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